Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer
Abstract Treatment for advanced-stage NSCLC generally includes the use of systemic chemotherapy as well as biologic therapies (targeted therapy) at later stages of the disease. However, in general, NSCLC is moderately sensitive to the currently available cytotoxic drugs, so the intention of chemothe...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Bergqvist, Michael [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2006 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Adis Data Information BV 2006 |
|---|
| Übergeordnetes Werk: |
Enthalten in: American Journal of Cancer - Springer International Publishing, 2002, 5(2006), 4 vom: Juli, Seite 223-244 |
|---|---|
| Übergeordnetes Werk: |
volume:5 ; year:2006 ; number:4 ; month:07 ; pages:223-244 |
| Links: |
|---|
| DOI / URN: |
10.2165/00024669-200605040-00003 |
|---|
| Katalog-ID: |
SPR035646373 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR035646373 | ||
| 003 | DE-627 | ||
| 005 | 20230519112246.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2006 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2165/00024669-200605040-00003 |2 doi | |
| 035 | |a (DE-627)SPR035646373 | ||
| 035 | |a (SPR)00024669-200605040-00003-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bergqvist, Michael |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer |
| 264 | 1 | |c 2006 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Adis Data Information BV 2006 | ||
| 520 | |a Abstract Treatment for advanced-stage NSCLC generally includes the use of systemic chemotherapy as well as biologic therapies (targeted therapy) at later stages of the disease. However, in general, NSCLC is moderately sensitive to the currently available cytotoxic drugs, so the intention of chemotherapeutic treatment in the advanced setting is mainly palliative. Several treatment regimens are available, but in the first-line setting, treatment traditions differ both within countries and between various parts of the world. The role of taxane-platinum chemotherapeutic combinations (mainly used in North America) has been questioned in the palliative setting since these combinations are known to cause neutropenia, skin and nail problems, as well as neurological toxicity. This review aims to summarize the current knowledge about the role of non-taxane therapy for patients with advanced NSCLC, with a focus on gemcitabine, vinorelbine, etoposide, pemetrexed, irinotecan, epidermal growth factor receptor (EGFR)-inhibiting agents, angiogenesis inhibitors, and small molecules. The compilation of literature in the present review indicates that the use of non-taxane treatment for patients with advanced NSCLC has an anti-tumor effect that is not different from that which can be seen with various taxane combinations. Furthermore, the combination of cisplatin with gemcitabine or vinorelbine seems to be a most compelling regimen in the first-line setting because of its modest toxicity (when administered by experienced staff), favorable clinical response, and relatively low drug cost. It is also clear that the novel therapies (EGFR inhibitors and inhibitors of angiogenesis) that have been approved so far will be of great clinical value; however, their use will be restricted to small, well defined, subpopulations of patients. The great challenge now is to define the populations benefiting from these novel therapies. | ||
| 650 | 4 | |a Epidermal Growth Factor Receptor |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Paclitaxel |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Bevacizumab |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Docetaxel |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Gemcitabine |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Sörenson, Svene |4 aut | |
| 700 | 1 | |a Brattström, Daniel |4 aut | |
| 700 | 1 | |a Mok, Tony |4 aut | |
| 700 | 1 | |a Henriksson, Roger |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American Journal of Cancer |d Springer International Publishing, 2002 |g 5(2006), 4 vom: Juli, Seite 223-244 |w (DE-627)SPR035643889 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2006 |g number:4 |g month:07 |g pages:223-244 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.2165/00024669-200605040-00003 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2006 |e 4 |c 07 |h 223-244 | ||
| author_variant |
m b mb s s ss d b db t m tm r h rh |
|---|---|
| matchkey_str |
bergqvistmichaelsrensonsvenebrattstrmdan:2006----:oefotxncnannceohrpiavnenn |
| hierarchy_sort_str |
2006 |
| publishDate |
2006 |
| allfields |
10.2165/00024669-200605040-00003 doi (DE-627)SPR035646373 (SPR)00024669-200605040-00003-e DE-627 ger DE-627 rakwb eng Bergqvist, Michael verfasserin aut Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer 2006 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis Data Information BV 2006 Abstract Treatment for advanced-stage NSCLC generally includes the use of systemic chemotherapy as well as biologic therapies (targeted therapy) at later stages of the disease. However, in general, NSCLC is moderately sensitive to the currently available cytotoxic drugs, so the intention of chemotherapeutic treatment in the advanced setting is mainly palliative. Several treatment regimens are available, but in the first-line setting, treatment traditions differ both within countries and between various parts of the world. The role of taxane-platinum chemotherapeutic combinations (mainly used in North America) has been questioned in the palliative setting since these combinations are known to cause neutropenia, skin and nail problems, as well as neurological toxicity. This review aims to summarize the current knowledge about the role of non-taxane therapy for patients with advanced NSCLC, with a focus on gemcitabine, vinorelbine, etoposide, pemetrexed, irinotecan, epidermal growth factor receptor (EGFR)-inhibiting agents, angiogenesis inhibitors, and small molecules. The compilation of literature in the present review indicates that the use of non-taxane treatment for patients with advanced NSCLC has an anti-tumor effect that is not different from that which can be seen with various taxane combinations. Furthermore, the combination of cisplatin with gemcitabine or vinorelbine seems to be a most compelling regimen in the first-line setting because of its modest toxicity (when administered by experienced staff), favorable clinical response, and relatively low drug cost. It is also clear that the novel therapies (EGFR inhibitors and inhibitors of angiogenesis) that have been approved so far will be of great clinical value; however, their use will be restricted to small, well defined, subpopulations of patients. The great challenge now is to define the populations benefiting from these novel therapies. Epidermal Growth Factor Receptor (dpeaa)DE-He213 Paclitaxel (dpeaa)DE-He213 Bevacizumab (dpeaa)DE-He213 Docetaxel (dpeaa)DE-He213 Gemcitabine (dpeaa)DE-He213 Sörenson, Svene aut Brattström, Daniel aut Mok, Tony aut Henriksson, Roger aut Enthalten in American Journal of Cancer Springer International Publishing, 2002 5(2006), 4 vom: Juli, Seite 223-244 (DE-627)SPR035643889 nnns volume:5 year:2006 number:4 month:07 pages:223-244 https://dx.doi.org/10.2165/00024669-200605040-00003 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 5 2006 4 07 223-244 |
| spelling |
10.2165/00024669-200605040-00003 doi (DE-627)SPR035646373 (SPR)00024669-200605040-00003-e DE-627 ger DE-627 rakwb eng Bergqvist, Michael verfasserin aut Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer 2006 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis Data Information BV 2006 Abstract Treatment for advanced-stage NSCLC generally includes the use of systemic chemotherapy as well as biologic therapies (targeted therapy) at later stages of the disease. However, in general, NSCLC is moderately sensitive to the currently available cytotoxic drugs, so the intention of chemotherapeutic treatment in the advanced setting is mainly palliative. Several treatment regimens are available, but in the first-line setting, treatment traditions differ both within countries and between various parts of the world. The role of taxane-platinum chemotherapeutic combinations (mainly used in North America) has been questioned in the palliative setting since these combinations are known to cause neutropenia, skin and nail problems, as well as neurological toxicity. This review aims to summarize the current knowledge about the role of non-taxane therapy for patients with advanced NSCLC, with a focus on gemcitabine, vinorelbine, etoposide, pemetrexed, irinotecan, epidermal growth factor receptor (EGFR)-inhibiting agents, angiogenesis inhibitors, and small molecules. The compilation of literature in the present review indicates that the use of non-taxane treatment for patients with advanced NSCLC has an anti-tumor effect that is not different from that which can be seen with various taxane combinations. Furthermore, the combination of cisplatin with gemcitabine or vinorelbine seems to be a most compelling regimen in the first-line setting because of its modest toxicity (when administered by experienced staff), favorable clinical response, and relatively low drug cost. It is also clear that the novel therapies (EGFR inhibitors and inhibitors of angiogenesis) that have been approved so far will be of great clinical value; however, their use will be restricted to small, well defined, subpopulations of patients. The great challenge now is to define the populations benefiting from these novel therapies. Epidermal Growth Factor Receptor (dpeaa)DE-He213 Paclitaxel (dpeaa)DE-He213 Bevacizumab (dpeaa)DE-He213 Docetaxel (dpeaa)DE-He213 Gemcitabine (dpeaa)DE-He213 Sörenson, Svene aut Brattström, Daniel aut Mok, Tony aut Henriksson, Roger aut Enthalten in American Journal of Cancer Springer International Publishing, 2002 5(2006), 4 vom: Juli, Seite 223-244 (DE-627)SPR035643889 nnns volume:5 year:2006 number:4 month:07 pages:223-244 https://dx.doi.org/10.2165/00024669-200605040-00003 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 5 2006 4 07 223-244 |
| allfields_unstemmed |
10.2165/00024669-200605040-00003 doi (DE-627)SPR035646373 (SPR)00024669-200605040-00003-e DE-627 ger DE-627 rakwb eng Bergqvist, Michael verfasserin aut Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer 2006 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis Data Information BV 2006 Abstract Treatment for advanced-stage NSCLC generally includes the use of systemic chemotherapy as well as biologic therapies (targeted therapy) at later stages of the disease. However, in general, NSCLC is moderately sensitive to the currently available cytotoxic drugs, so the intention of chemotherapeutic treatment in the advanced setting is mainly palliative. Several treatment regimens are available, but in the first-line setting, treatment traditions differ both within countries and between various parts of the world. The role of taxane-platinum chemotherapeutic combinations (mainly used in North America) has been questioned in the palliative setting since these combinations are known to cause neutropenia, skin and nail problems, as well as neurological toxicity. This review aims to summarize the current knowledge about the role of non-taxane therapy for patients with advanced NSCLC, with a focus on gemcitabine, vinorelbine, etoposide, pemetrexed, irinotecan, epidermal growth factor receptor (EGFR)-inhibiting agents, angiogenesis inhibitors, and small molecules. The compilation of literature in the present review indicates that the use of non-taxane treatment for patients with advanced NSCLC has an anti-tumor effect that is not different from that which can be seen with various taxane combinations. Furthermore, the combination of cisplatin with gemcitabine or vinorelbine seems to be a most compelling regimen in the first-line setting because of its modest toxicity (when administered by experienced staff), favorable clinical response, and relatively low drug cost. It is also clear that the novel therapies (EGFR inhibitors and inhibitors of angiogenesis) that have been approved so far will be of great clinical value; however, their use will be restricted to small, well defined, subpopulations of patients. The great challenge now is to define the populations benefiting from these novel therapies. Epidermal Growth Factor Receptor (dpeaa)DE-He213 Paclitaxel (dpeaa)DE-He213 Bevacizumab (dpeaa)DE-He213 Docetaxel (dpeaa)DE-He213 Gemcitabine (dpeaa)DE-He213 Sörenson, Svene aut Brattström, Daniel aut Mok, Tony aut Henriksson, Roger aut Enthalten in American Journal of Cancer Springer International Publishing, 2002 5(2006), 4 vom: Juli, Seite 223-244 (DE-627)SPR035643889 nnns volume:5 year:2006 number:4 month:07 pages:223-244 https://dx.doi.org/10.2165/00024669-200605040-00003 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 5 2006 4 07 223-244 |
| allfieldsGer |
10.2165/00024669-200605040-00003 doi (DE-627)SPR035646373 (SPR)00024669-200605040-00003-e DE-627 ger DE-627 rakwb eng Bergqvist, Michael verfasserin aut Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer 2006 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis Data Information BV 2006 Abstract Treatment for advanced-stage NSCLC generally includes the use of systemic chemotherapy as well as biologic therapies (targeted therapy) at later stages of the disease. However, in general, NSCLC is moderately sensitive to the currently available cytotoxic drugs, so the intention of chemotherapeutic treatment in the advanced setting is mainly palliative. Several treatment regimens are available, but in the first-line setting, treatment traditions differ both within countries and between various parts of the world. The role of taxane-platinum chemotherapeutic combinations (mainly used in North America) has been questioned in the palliative setting since these combinations are known to cause neutropenia, skin and nail problems, as well as neurological toxicity. This review aims to summarize the current knowledge about the role of non-taxane therapy for patients with advanced NSCLC, with a focus on gemcitabine, vinorelbine, etoposide, pemetrexed, irinotecan, epidermal growth factor receptor (EGFR)-inhibiting agents, angiogenesis inhibitors, and small molecules. The compilation of literature in the present review indicates that the use of non-taxane treatment for patients with advanced NSCLC has an anti-tumor effect that is not different from that which can be seen with various taxane combinations. Furthermore, the combination of cisplatin with gemcitabine or vinorelbine seems to be a most compelling regimen in the first-line setting because of its modest toxicity (when administered by experienced staff), favorable clinical response, and relatively low drug cost. It is also clear that the novel therapies (EGFR inhibitors and inhibitors of angiogenesis) that have been approved so far will be of great clinical value; however, their use will be restricted to small, well defined, subpopulations of patients. The great challenge now is to define the populations benefiting from these novel therapies. Epidermal Growth Factor Receptor (dpeaa)DE-He213 Paclitaxel (dpeaa)DE-He213 Bevacizumab (dpeaa)DE-He213 Docetaxel (dpeaa)DE-He213 Gemcitabine (dpeaa)DE-He213 Sörenson, Svene aut Brattström, Daniel aut Mok, Tony aut Henriksson, Roger aut Enthalten in American Journal of Cancer Springer International Publishing, 2002 5(2006), 4 vom: Juli, Seite 223-244 (DE-627)SPR035643889 nnns volume:5 year:2006 number:4 month:07 pages:223-244 https://dx.doi.org/10.2165/00024669-200605040-00003 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 5 2006 4 07 223-244 |
| allfieldsSound |
10.2165/00024669-200605040-00003 doi (DE-627)SPR035646373 (SPR)00024669-200605040-00003-e DE-627 ger DE-627 rakwb eng Bergqvist, Michael verfasserin aut Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer 2006 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis Data Information BV 2006 Abstract Treatment for advanced-stage NSCLC generally includes the use of systemic chemotherapy as well as biologic therapies (targeted therapy) at later stages of the disease. However, in general, NSCLC is moderately sensitive to the currently available cytotoxic drugs, so the intention of chemotherapeutic treatment in the advanced setting is mainly palliative. Several treatment regimens are available, but in the first-line setting, treatment traditions differ both within countries and between various parts of the world. The role of taxane-platinum chemotherapeutic combinations (mainly used in North America) has been questioned in the palliative setting since these combinations are known to cause neutropenia, skin and nail problems, as well as neurological toxicity. This review aims to summarize the current knowledge about the role of non-taxane therapy for patients with advanced NSCLC, with a focus on gemcitabine, vinorelbine, etoposide, pemetrexed, irinotecan, epidermal growth factor receptor (EGFR)-inhibiting agents, angiogenesis inhibitors, and small molecules. The compilation of literature in the present review indicates that the use of non-taxane treatment for patients with advanced NSCLC has an anti-tumor effect that is not different from that which can be seen with various taxane combinations. Furthermore, the combination of cisplatin with gemcitabine or vinorelbine seems to be a most compelling regimen in the first-line setting because of its modest toxicity (when administered by experienced staff), favorable clinical response, and relatively low drug cost. It is also clear that the novel therapies (EGFR inhibitors and inhibitors of angiogenesis) that have been approved so far will be of great clinical value; however, their use will be restricted to small, well defined, subpopulations of patients. The great challenge now is to define the populations benefiting from these novel therapies. Epidermal Growth Factor Receptor (dpeaa)DE-He213 Paclitaxel (dpeaa)DE-He213 Bevacizumab (dpeaa)DE-He213 Docetaxel (dpeaa)DE-He213 Gemcitabine (dpeaa)DE-He213 Sörenson, Svene aut Brattström, Daniel aut Mok, Tony aut Henriksson, Roger aut Enthalten in American Journal of Cancer Springer International Publishing, 2002 5(2006), 4 vom: Juli, Seite 223-244 (DE-627)SPR035643889 nnns volume:5 year:2006 number:4 month:07 pages:223-244 https://dx.doi.org/10.2165/00024669-200605040-00003 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 5 2006 4 07 223-244 |
| language |
English |
| source |
Enthalten in American Journal of Cancer 5(2006), 4 vom: Juli, Seite 223-244 volume:5 year:2006 number:4 month:07 pages:223-244 |
| sourceStr |
Enthalten in American Journal of Cancer 5(2006), 4 vom: Juli, Seite 223-244 volume:5 year:2006 number:4 month:07 pages:223-244 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Epidermal Growth Factor Receptor Paclitaxel Bevacizumab Docetaxel Gemcitabine |
| isfreeaccess_bool |
false |
| container_title |
American Journal of Cancer |
| authorswithroles_txt_mv |
Bergqvist, Michael @@aut@@ Sörenson, Svene @@aut@@ Brattström, Daniel @@aut@@ Mok, Tony @@aut@@ Henriksson, Roger @@aut@@ |
| publishDateDaySort_date |
2006-07-01T00:00:00Z |
| hierarchy_top_id |
SPR035643889 |
| id |
SPR035646373 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR035646373</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519112246.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2006 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00024669-200605040-00003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR035646373</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00024669-200605040-00003-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bergqvist, Michael</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2006</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis Data Information BV 2006</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Treatment for advanced-stage NSCLC generally includes the use of systemic chemotherapy as well as biologic therapies (targeted therapy) at later stages of the disease. However, in general, NSCLC is moderately sensitive to the currently available cytotoxic drugs, so the intention of chemotherapeutic treatment in the advanced setting is mainly palliative. Several treatment regimens are available, but in the first-line setting, treatment traditions differ both within countries and between various parts of the world. The role of taxane-platinum chemotherapeutic combinations (mainly used in North America) has been questioned in the palliative setting since these combinations are known to cause neutropenia, skin and nail problems, as well as neurological toxicity. This review aims to summarize the current knowledge about the role of non-taxane therapy for patients with advanced NSCLC, with a focus on gemcitabine, vinorelbine, etoposide, pemetrexed, irinotecan, epidermal growth factor receptor (EGFR)-inhibiting agents, angiogenesis inhibitors, and small molecules. The compilation of literature in the present review indicates that the use of non-taxane treatment for patients with advanced NSCLC has an anti-tumor effect that is not different from that which can be seen with various taxane combinations. Furthermore, the combination of cisplatin with gemcitabine or vinorelbine seems to be a most compelling regimen in the first-line setting because of its modest toxicity (when administered by experienced staff), favorable clinical response, and relatively low drug cost. It is also clear that the novel therapies (EGFR inhibitors and inhibitors of angiogenesis) that have been approved so far will be of great clinical value; however, their use will be restricted to small, well defined, subpopulations of patients. The great challenge now is to define the populations benefiting from these novel therapies.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Epidermal Growth Factor Receptor</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Paclitaxel</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bevacizumab</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Docetaxel</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gemcitabine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sörenson, Svene</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brattström, Daniel</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mok, Tony</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Henriksson, Roger</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">American Journal of Cancer</subfield><subfield code="d">Springer International Publishing, 2002</subfield><subfield code="g">5(2006), 4 vom: Juli, Seite 223-244</subfield><subfield code="w">(DE-627)SPR035643889</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:5</subfield><subfield code="g">year:2006</subfield><subfield code="g">number:4</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:223-244</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00024669-200605040-00003</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">5</subfield><subfield code="j">2006</subfield><subfield code="e">4</subfield><subfield code="c">07</subfield><subfield code="h">223-244</subfield></datafield></record></collection>
|
| author |
Bergqvist, Michael |
| spellingShingle |
Bergqvist, Michael misc Epidermal Growth Factor Receptor misc Paclitaxel misc Bevacizumab misc Docetaxel misc Gemcitabine Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer |
| authorStr |
Bergqvist, Michael |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR035643889 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer Epidermal Growth Factor Receptor (dpeaa)DE-He213 Paclitaxel (dpeaa)DE-He213 Bevacizumab (dpeaa)DE-He213 Docetaxel (dpeaa)DE-He213 Gemcitabine (dpeaa)DE-He213 |
| topic |
misc Epidermal Growth Factor Receptor misc Paclitaxel misc Bevacizumab misc Docetaxel misc Gemcitabine |
| topic_unstemmed |
misc Epidermal Growth Factor Receptor misc Paclitaxel misc Bevacizumab misc Docetaxel misc Gemcitabine |
| topic_browse |
misc Epidermal Growth Factor Receptor misc Paclitaxel misc Bevacizumab misc Docetaxel misc Gemcitabine |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
American Journal of Cancer |
| hierarchy_parent_id |
SPR035643889 |
| hierarchy_top_title |
American Journal of Cancer |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR035643889 |
| title |
Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer |
| ctrlnum |
(DE-627)SPR035646373 (SPR)00024669-200605040-00003-e |
| title_full |
Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer |
| author_sort |
Bergqvist, Michael |
| journal |
American Journal of Cancer |
| journalStr |
American Journal of Cancer |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2006 |
| contenttype_str_mv |
txt |
| container_start_page |
223 |
| author_browse |
Bergqvist, Michael Sörenson, Svene Brattström, Daniel Mok, Tony Henriksson, Roger |
| container_volume |
5 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Bergqvist, Michael |
| doi_str_mv |
10.2165/00024669-200605040-00003 |
| title_sort |
role of non-taxane-containing chemotherapy in advanced non-small cell lung cancer |
| title_auth |
Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer |
| abstract |
Abstract Treatment for advanced-stage NSCLC generally includes the use of systemic chemotherapy as well as biologic therapies (targeted therapy) at later stages of the disease. However, in general, NSCLC is moderately sensitive to the currently available cytotoxic drugs, so the intention of chemotherapeutic treatment in the advanced setting is mainly palliative. Several treatment regimens are available, but in the first-line setting, treatment traditions differ both within countries and between various parts of the world. The role of taxane-platinum chemotherapeutic combinations (mainly used in North America) has been questioned in the palliative setting since these combinations are known to cause neutropenia, skin and nail problems, as well as neurological toxicity. This review aims to summarize the current knowledge about the role of non-taxane therapy for patients with advanced NSCLC, with a focus on gemcitabine, vinorelbine, etoposide, pemetrexed, irinotecan, epidermal growth factor receptor (EGFR)-inhibiting agents, angiogenesis inhibitors, and small molecules. The compilation of literature in the present review indicates that the use of non-taxane treatment for patients with advanced NSCLC has an anti-tumor effect that is not different from that which can be seen with various taxane combinations. Furthermore, the combination of cisplatin with gemcitabine or vinorelbine seems to be a most compelling regimen in the first-line setting because of its modest toxicity (when administered by experienced staff), favorable clinical response, and relatively low drug cost. It is also clear that the novel therapies (EGFR inhibitors and inhibitors of angiogenesis) that have been approved so far will be of great clinical value; however, their use will be restricted to small, well defined, subpopulations of patients. The great challenge now is to define the populations benefiting from these novel therapies. © Adis Data Information BV 2006 |
| abstractGer |
Abstract Treatment for advanced-stage NSCLC generally includes the use of systemic chemotherapy as well as biologic therapies (targeted therapy) at later stages of the disease. However, in general, NSCLC is moderately sensitive to the currently available cytotoxic drugs, so the intention of chemotherapeutic treatment in the advanced setting is mainly palliative. Several treatment regimens are available, but in the first-line setting, treatment traditions differ both within countries and between various parts of the world. The role of taxane-platinum chemotherapeutic combinations (mainly used in North America) has been questioned in the palliative setting since these combinations are known to cause neutropenia, skin and nail problems, as well as neurological toxicity. This review aims to summarize the current knowledge about the role of non-taxane therapy for patients with advanced NSCLC, with a focus on gemcitabine, vinorelbine, etoposide, pemetrexed, irinotecan, epidermal growth factor receptor (EGFR)-inhibiting agents, angiogenesis inhibitors, and small molecules. The compilation of literature in the present review indicates that the use of non-taxane treatment for patients with advanced NSCLC has an anti-tumor effect that is not different from that which can be seen with various taxane combinations. Furthermore, the combination of cisplatin with gemcitabine or vinorelbine seems to be a most compelling regimen in the first-line setting because of its modest toxicity (when administered by experienced staff), favorable clinical response, and relatively low drug cost. It is also clear that the novel therapies (EGFR inhibitors and inhibitors of angiogenesis) that have been approved so far will be of great clinical value; however, their use will be restricted to small, well defined, subpopulations of patients. The great challenge now is to define the populations benefiting from these novel therapies. © Adis Data Information BV 2006 |
| abstract_unstemmed |
Abstract Treatment for advanced-stage NSCLC generally includes the use of systemic chemotherapy as well as biologic therapies (targeted therapy) at later stages of the disease. However, in general, NSCLC is moderately sensitive to the currently available cytotoxic drugs, so the intention of chemotherapeutic treatment in the advanced setting is mainly palliative. Several treatment regimens are available, but in the first-line setting, treatment traditions differ both within countries and between various parts of the world. The role of taxane-platinum chemotherapeutic combinations (mainly used in North America) has been questioned in the palliative setting since these combinations are known to cause neutropenia, skin and nail problems, as well as neurological toxicity. This review aims to summarize the current knowledge about the role of non-taxane therapy for patients with advanced NSCLC, with a focus on gemcitabine, vinorelbine, etoposide, pemetrexed, irinotecan, epidermal growth factor receptor (EGFR)-inhibiting agents, angiogenesis inhibitors, and small molecules. The compilation of literature in the present review indicates that the use of non-taxane treatment for patients with advanced NSCLC has an anti-tumor effect that is not different from that which can be seen with various taxane combinations. Furthermore, the combination of cisplatin with gemcitabine or vinorelbine seems to be a most compelling regimen in the first-line setting because of its modest toxicity (when administered by experienced staff), favorable clinical response, and relatively low drug cost. It is also clear that the novel therapies (EGFR inhibitors and inhibitors of angiogenesis) that have been approved so far will be of great clinical value; however, their use will be restricted to small, well defined, subpopulations of patients. The great challenge now is to define the populations benefiting from these novel therapies. © Adis Data Information BV 2006 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA |
| container_issue |
4 |
| title_short |
Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer |
| url |
https://dx.doi.org/10.2165/00024669-200605040-00003 |
| remote_bool |
true |
| author2 |
Sörenson, Svene Brattström, Daniel Mok, Tony Henriksson, Roger |
| author2Str |
Sörenson, Svene Brattström, Daniel Mok, Tony Henriksson, Roger |
| ppnlink |
SPR035643889 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.2165/00024669-200605040-00003 |
| up_date |
2024-07-03T15:29:57.624Z |
| _version_ |
1803572318177329152 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR035646373</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519112246.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2006 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00024669-200605040-00003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR035646373</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00024669-200605040-00003-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bergqvist, Michael</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2006</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis Data Information BV 2006</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Treatment for advanced-stage NSCLC generally includes the use of systemic chemotherapy as well as biologic therapies (targeted therapy) at later stages of the disease. However, in general, NSCLC is moderately sensitive to the currently available cytotoxic drugs, so the intention of chemotherapeutic treatment in the advanced setting is mainly palliative. Several treatment regimens are available, but in the first-line setting, treatment traditions differ both within countries and between various parts of the world. The role of taxane-platinum chemotherapeutic combinations (mainly used in North America) has been questioned in the palliative setting since these combinations are known to cause neutropenia, skin and nail problems, as well as neurological toxicity. This review aims to summarize the current knowledge about the role of non-taxane therapy for patients with advanced NSCLC, with a focus on gemcitabine, vinorelbine, etoposide, pemetrexed, irinotecan, epidermal growth factor receptor (EGFR)-inhibiting agents, angiogenesis inhibitors, and small molecules. The compilation of literature in the present review indicates that the use of non-taxane treatment for patients with advanced NSCLC has an anti-tumor effect that is not different from that which can be seen with various taxane combinations. Furthermore, the combination of cisplatin with gemcitabine or vinorelbine seems to be a most compelling regimen in the first-line setting because of its modest toxicity (when administered by experienced staff), favorable clinical response, and relatively low drug cost. It is also clear that the novel therapies (EGFR inhibitors and inhibitors of angiogenesis) that have been approved so far will be of great clinical value; however, their use will be restricted to small, well defined, subpopulations of patients. The great challenge now is to define the populations benefiting from these novel therapies.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Epidermal Growth Factor Receptor</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Paclitaxel</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bevacizumab</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Docetaxel</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gemcitabine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sörenson, Svene</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brattström, Daniel</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mok, Tony</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Henriksson, Roger</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">American Journal of Cancer</subfield><subfield code="d">Springer International Publishing, 2002</subfield><subfield code="g">5(2006), 4 vom: Juli, Seite 223-244</subfield><subfield code="w">(DE-627)SPR035643889</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:5</subfield><subfield code="g">year:2006</subfield><subfield code="g">number:4</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:223-244</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00024669-200605040-00003</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">5</subfield><subfield code="j">2006</subfield><subfield code="e">4</subfield><subfield code="c">07</subfield><subfield code="h">223-244</subfield></datafield></record></collection>
|
| score |
7.398798 |